LLGL2 rescues nutrient stress by promoting leucine uptake in ER+ breast cancer

Yasuhiro Saito, Lewyn Li, Etienne Coyaud, Augustin Luna, Chris Sander, Brian Raught, John M. Asara, Myles Brown and Senthil K. Muthuswamy ()
Additional contact information
Yasuhiro Saito: Beth Israel Deaconess Medical Center, Harvard Medical School
Lewyn Li: Dana-Farber Cancer Institute
Etienne Coyaud: University Health Network
Augustin Luna: Dana-Farber Cancer Institute
Chris Sander: Dana-Farber Cancer Institute
Brian Raught: University Health Network
John M. Asara: Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School
Myles Brown: Dana-Farber Cancer Institute
Senthil K. Muthuswamy: Beth Israel Deaconess Medical Center, Harvard Medical School

Nature, 2019, vol. 569, issue 7755, 275-279

Abstract: Abstract Drosophila Lgl and its mammalian homologues, LLGL1 and LLGL2, are scaffolding proteins that regulate the establishment of apical–basal polarity in epithelial cells1,2. Whereas Lgl functions as a tumour suppressor in Drosophila1, the roles of mammalian LLGL1 and LLGL2 in cancer are unclear. The majority (about 75%) of breast cancers express oestrogen receptors (ERs)3, and patients with these tumours receive endocrine treatment4. However, the development of resistance to endocrine therapy and metastatic progression are leading causes of death for patients with ER+ disease4. Here we report that, unlike LLGL1, LLGL2 is overexpressed in ER+ breast cancer and promotes cell proliferation under nutrient stress. LLGL2 regulates cell surface levels of a leucine transporter, SLC7A5, by forming a trimeric complex with SLC7A5 and a regulator of membrane fusion, YKT6, to promote leucine uptake and cell proliferation. The oestrogen receptor targets LLGL2 expression. Resistance to endocrine treatment in breast cancer cells was associated with SLC7A5- and LLGL2-dependent adaption to nutrient stress. SLC7A5 was necessary and sufficient to confer resistance to tamoxifen treatment, identifying SLC7A5 as a potential therapeutic target for overcoming resistance to endocrine treatments in breast cancer. Thus, LLGL2 functions as a promoter of tumour growth and not as a tumour suppressor in ER+ breast cancer. Beyond breast cancer, adaptation to nutrient stress is critically important5, and our findings identify an unexpected role for LLGL2 in this process.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41586-019-1126-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:569:y:2019:i:7755:d:10.1038_s41586-019-1126-2

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-019-1126-2

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().